Key Takeaways:
INNOVENT BIO (01801.HK) reported 1H26 net profit of RMB1.25 billion, up 50.2 percent year over year, beating market consensus.
"The results beat both our and market expectations, driven by operating expense efficiencies despite higher R&D spending," Goldman Sachs said in a research report, raising its target price from HKD111.68 to HKD120.6 with a Buy rating.
Total revenue reached RMB8.62 billion, up 44.8 percent year over year, while product sales revenue climbed 56.7 percent to RMB8.2 billion. Adjusted net profit gained 40.5 percent to RMB1.7 billion, also above Daiwa's expectations and market consensus. CLSA raised its target price from HKD139.9 to HKD146.1, maintaining an Outperform rating and calling the stock one of its top picks in China's biotech sector.
The company set a 2030 revenue target of RMB35-40 billion, a leap from its 2027 product revenue guidance of RMB20 billion, reflecting growth momentum across oncology and general healthcare. Shares surged 8.09 percent to HKD108.2 with turnover of HKD2.756 billion, while the short-selling ratio stood at 20.475 percent, suggesting potential short-covering pressure.
Goldman Sachs updated its 2026-28 EPS forecasts to RMB1.79, RMB3.50 and RMB4.68 respectively, reflecting the 1H26 results and slight adjustments to operating expenses. Daiwa noted the first-time proposal of a 2030 revenue target was a major positive surprise, representing a leapfrog from the previously proposed 2027 product revenue guidance of RMB20 billion.
Innovent held RMB30.2 billion in cash reserves as of July 31, 2026, equivalent to roughly US$4.5 billion. The company has entered strategic collaborations with Takeda, Eli Lilly and Pfizer over the past 10 months, with aggregate deal value reaching US$34 billion across more than 20 pipeline programs, including five co-development and co-commercialization assets.
The company's 2030 strategy targets advancing at least five molecules into global multi-regional Phase 3 development and achieving product launches in the U.S. and Europe. Innovent operates 140,000 liters of total manufacturing capacity across its Suzhou and Hangzhou sites.
The earnings beat and upward revisions from multiple top-tier brokers could drive continued buying momentum in INNOVENT BIO shares and lift sentiment across the China biotech sector. Investors will watch for progress on the company's global Phase 3 trials and partnership milestones in the coming quarters.
This article is for informational purposes only and does not constitute investment advice.
